The Q1 conf-call clarified some doubts. The biggest point was in response where it was mentioned PTC can’t trade on HEX. This to me was single most important piece of information.
Invested from lower level. Was is wait and watch mode. Will remain so till HEX launched other segments and we see impact of those launches.
Thank you @StonePitbull this is super helpful. just to summarize
For anchor investors who buys in the IPO which is just one day before it opens for general subscription – lock-in 30 days (which is now 90 days i believe)
For VC’s or the promoter: lock-in period is one year.
As per some articles, it is mentioned that one year period is applicable for companies which does not have an identified promoter. I believe it should be applicable for promoter held entities as well ?
Q1 FY23 Results
Presentation
Financials
(post deleted by author)
In my opinion, good, steady & predictable topline growth in Q1 results declared an hour ago.
RM cost pressure has increased further resulting in net profit below 30%. This needs to be waited out for how many every quarters it takes.
Hope the capex is also moving as per plan. We would get more details in the con call
Laurus Q1 FY23 Results Press release
Revenue at ₹ 1,539 crs, up 20 % (Y-o-Y)
EBITDA ₹ 454 crs, increased by 14 % (Y-o-Y)
EBITDA margins at 29.5 %
PAT at ₹ 251 crs, increased by 4 % (Y-o-Y)
PAT margins at 16.3 %
EPS (Diluted) for the period at ₹ 4.7 per share (not annualised)
Chief Executive Officer Dr. Satyanarayana Chava stated
“Laurus Lab’s performance in the first quarter of the current financial year reflects our efforts towards strengthening and diversifying our business by an increased focus on Non-ARV APIs and Formulations and high-growth CDMO segments. This strong momentum has been delivered because of our efforts toward a sustainable supply chain, capacity creation, and on-time delivery of products during the current challenging environment. Pricing pressure in ARV APIs and the Formulation business was significant during this quarter, and ARV FDF volumes would increase in the coming quarters. The high-margin CDMO business growth helped the organization deliver very good revenue
and profit.
Business Highlights
Overall
Total Income for Q1FY23 at ₹ 1,539 crs with 20% growth (Y-o-Y).
Performance driven by strong traction in Synthesis business (+196% YoY), and Other APIs
which more than compensated for overall ARV business decline
R & D spent of ₹ 49 crs (3 % of Revenues)
Generic FDF
FDF business generated revenue of ₹ 349 Cr during Q1, decreased by 33% YoY Growth was impacted by lower ARV business while Developed market sales stable with higher generic volumes offset by pricing pressure
During Q1, 1 product dossiers were filed in Developed markets and a total of 3 approvals were
received (including Tentative)
Cumulatively filed 32 ANDAs in US with 15 PARA IV filings and 11 FTF opportunities
Brownfield capacity expansion at Unit 2 commissioned during the quarter
Generic API
API business reported revenue of ₹ 583 Cr during Q1, increased by 6% YoY
Other APIs sustained strong growth +79% YoY
Oncology revenues grew at modest pace +5% YoY
ARV business continue to witness healthy sequential improvement supported by channel stock
easing and better volumes
Filed 325 patents out of that 192 patents granted as of June’22
Filed 74 DMFs till date.
Synthesis
Delivered accelerated growth of 196% during Q1 to ₹ 577 crs
The growth was supported by solid demand from new and existing clients
Actively working on over 50 projects and On-going supplies for four commercial projects
Expansion in CDMO capability on track to include new opportunities and extended service
Greenfield investment to set up a dedicated R&D center and manufacturing units is progressing
as per our expectations
Bio Division
Laurus Bio segment was largely stable and clocked Q1 sales of ₹ 30 cr
Fully operational benefits of new capacities to reflect through FY23
Continue to work on Improving Products offering and Improving Go-to-market
Evaluating few land parcel to Create close to 1 million litres fermentation capacity
Investor presentation:
SCO_IS_KM_322072710420 (bseindia.com)
Q1 Results
SCO_IS_KM_322072710420 (bseindia.com)
There you go…VC Investors we’re given a 1 year deadline before selling their shares so as to not make spoilsport of the IPO
Beauty lies in the eye of the beholder.! Stock was trading at 100x PE 6 months ago, still trading at 45x PE. So you may call it expensive (or not), depends on your own analysis.
If we look at the quality of the business and the moat around it (which is what matters in long term I believe), the model looks very difficult to beat.
One of a kind platform with multiple solutions to a region’s energy issues (IEX is providing services to almost all of South Asia now), low transaction cost for customers (2 paise cost on 5 rupee cost/unit, how much discount can the competition really offer) and innovative, prudent & honest management (went for IGX when no one was even talking about it, launching new products, bonus share issue etc).
So the company looks very enticing, valuations is something everyone has to decide individually.
Please help to answer the question.
why there is so much hype for zomato one year lock-in period. is this applicable for all companies?
is there a website which tracks this lock-in end date and percentage of shares which are locked (like 50% of total outstanding shares), looks like this is exactly one year after listing date.